A novel biomarker of cardiometabolic pathology in schizophrenia?

Ellen E. Lee, Dorothy D. Sears, Jinyuan Liu, Hua Jin, Xin M. Tu, Lisa T. Eyler, Dilip V. Jeste

Research output: Contribution to journalArticle

Abstract

Background: Persons with schizophrenia and schizoaffective disorder (PwS) have high rates of cardiometabolic pathology that contributes to premature mortality. Adiponectin is a metabolic hormone affecting insulin sensitivity and inflammation, and is active in the brain. High-molecular weight (HMW) adiponectin is considered a more sensitive marker of metabolic dysfunction than total adiponectin, but has been poorly studied in schizophrenia. Methods: This was a cross-sectional study of 100 PwS, age range 26–68 years (46 women), and 93 age- and sex-comparable non-psychiatric comparison (NC) subjects. Assessments included measures of psychopathology, physical health, cognitive function, and circulating biomarkers of metabolic dysfunction (HMW adiponectin, lipids, insulin resistance) and inflammation (high-sensitivity C-reactive protein or hs-CRP, Tumor Necrosis Factor-α, Interleukin-6, and Interleukin-10). Results: HMW adiponectin levels were lower in PwS compared to NCs. Lower HMW adiponectin levels were associated with higher body mass index (BMI), higher Framingham risk for coronary heart disease, higher number of metabolic syndrome criteria, greater insulin resistance, lower HDL cholesterol, and higher hs-CRP in both groups. Only in PwS, lower HMW adiponectin correlated with younger age. In the best-fit regression models of HMW adiponectin, lower levels were associated with lower HDL cholesterol and minority race/ethnicity in both groups; but with younger age, non-smoking, higher insulin resistance, and a diagnosis of schizoaffective disorder only among PwS, and with male sex, better cognitive functioning, and higher hs-CRP levels in NCs only. Discussion: HMW adiponectin may be a promising biomarker of cardiometabolic health, especially among PwS. Adiponectin is a potential target for lifestyle and pharmacological interventions. Research on the possible role of HMW adiponectin in modifying cardiometabolic pathology in schizophrenia is needed.

Original languageEnglish (US)
Pages (from-to)31-37
Number of pages7
JournalJournal of Psychiatric Research
Volume117
DOIs
StatePublished - Oct 2019
Externally publishedYes

Fingerprint

Adiponectin
Schizophrenia
Biomarkers
Pathology
Molecular Weight
Insulin Resistance
Psychotic Disorders
HDL Cholesterol
Inflammation
Premature Mortality
Health
Psychopathology
Interleukin-10
C-Reactive Protein
Cognition
Coronary Disease
Life Style
Interleukin-6
Body Mass Index
Tumor Necrosis Factor-alpha

Keywords

  • Adipokines
  • Aging
  • Body mass index
  • Cytokines
  • Hemoglobin A1C
  • Insulin resistance

ASJC Scopus subject areas

  • Psychiatry and Mental health
  • Biological Psychiatry

Cite this

A novel biomarker of cardiometabolic pathology in schizophrenia? / Lee, Ellen E.; Sears, Dorothy D.; Liu, Jinyuan; Jin, Hua; Tu, Xin M.; Eyler, Lisa T.; Jeste, Dilip V.

In: Journal of Psychiatric Research, Vol. 117, 10.2019, p. 31-37.

Research output: Contribution to journalArticle

Lee, Ellen E. ; Sears, Dorothy D. ; Liu, Jinyuan ; Jin, Hua ; Tu, Xin M. ; Eyler, Lisa T. ; Jeste, Dilip V. / A novel biomarker of cardiometabolic pathology in schizophrenia?. In: Journal of Psychiatric Research. 2019 ; Vol. 117. pp. 31-37.
@article{69d060d93151477f98648fc8a73ed5bf,
title = "A novel biomarker of cardiometabolic pathology in schizophrenia?",
abstract = "Background: Persons with schizophrenia and schizoaffective disorder (PwS) have high rates of cardiometabolic pathology that contributes to premature mortality. Adiponectin is a metabolic hormone affecting insulin sensitivity and inflammation, and is active in the brain. High-molecular weight (HMW) adiponectin is considered a more sensitive marker of metabolic dysfunction than total adiponectin, but has been poorly studied in schizophrenia. Methods: This was a cross-sectional study of 100 PwS, age range 26–68 years (46 women), and 93 age- and sex-comparable non-psychiatric comparison (NC) subjects. Assessments included measures of psychopathology, physical health, cognitive function, and circulating biomarkers of metabolic dysfunction (HMW adiponectin, lipids, insulin resistance) and inflammation (high-sensitivity C-reactive protein or hs-CRP, Tumor Necrosis Factor-α, Interleukin-6, and Interleukin-10). Results: HMW adiponectin levels were lower in PwS compared to NCs. Lower HMW adiponectin levels were associated with higher body mass index (BMI), higher Framingham risk for coronary heart disease, higher number of metabolic syndrome criteria, greater insulin resistance, lower HDL cholesterol, and higher hs-CRP in both groups. Only in PwS, lower HMW adiponectin correlated with younger age. In the best-fit regression models of HMW adiponectin, lower levels were associated with lower HDL cholesterol and minority race/ethnicity in both groups; but with younger age, non-smoking, higher insulin resistance, and a diagnosis of schizoaffective disorder only among PwS, and with male sex, better cognitive functioning, and higher hs-CRP levels in NCs only. Discussion: HMW adiponectin may be a promising biomarker of cardiometabolic health, especially among PwS. Adiponectin is a potential target for lifestyle and pharmacological interventions. Research on the possible role of HMW adiponectin in modifying cardiometabolic pathology in schizophrenia is needed.",
keywords = "Adipokines, Aging, Body mass index, Cytokines, Hemoglobin A1C, Insulin resistance",
author = "Lee, {Ellen E.} and Sears, {Dorothy D.} and Jinyuan Liu and Hua Jin and Tu, {Xin M.} and Eyler, {Lisa T.} and Jeste, {Dilip V.}",
year = "2019",
month = "10",
doi = "10.1016/j.jpsychires.2019.06.011",
language = "English (US)",
volume = "117",
pages = "31--37",
journal = "Journal of Psychiatric Research",
issn = "0022-3956",
publisher = "Elsevier Limited",

}

TY - JOUR

T1 - A novel biomarker of cardiometabolic pathology in schizophrenia?

AU - Lee, Ellen E.

AU - Sears, Dorothy D.

AU - Liu, Jinyuan

AU - Jin, Hua

AU - Tu, Xin M.

AU - Eyler, Lisa T.

AU - Jeste, Dilip V.

PY - 2019/10

Y1 - 2019/10

N2 - Background: Persons with schizophrenia and schizoaffective disorder (PwS) have high rates of cardiometabolic pathology that contributes to premature mortality. Adiponectin is a metabolic hormone affecting insulin sensitivity and inflammation, and is active in the brain. High-molecular weight (HMW) adiponectin is considered a more sensitive marker of metabolic dysfunction than total adiponectin, but has been poorly studied in schizophrenia. Methods: This was a cross-sectional study of 100 PwS, age range 26–68 years (46 women), and 93 age- and sex-comparable non-psychiatric comparison (NC) subjects. Assessments included measures of psychopathology, physical health, cognitive function, and circulating biomarkers of metabolic dysfunction (HMW adiponectin, lipids, insulin resistance) and inflammation (high-sensitivity C-reactive protein or hs-CRP, Tumor Necrosis Factor-α, Interleukin-6, and Interleukin-10). Results: HMW adiponectin levels were lower in PwS compared to NCs. Lower HMW adiponectin levels were associated with higher body mass index (BMI), higher Framingham risk for coronary heart disease, higher number of metabolic syndrome criteria, greater insulin resistance, lower HDL cholesterol, and higher hs-CRP in both groups. Only in PwS, lower HMW adiponectin correlated with younger age. In the best-fit regression models of HMW adiponectin, lower levels were associated with lower HDL cholesterol and minority race/ethnicity in both groups; but with younger age, non-smoking, higher insulin resistance, and a diagnosis of schizoaffective disorder only among PwS, and with male sex, better cognitive functioning, and higher hs-CRP levels in NCs only. Discussion: HMW adiponectin may be a promising biomarker of cardiometabolic health, especially among PwS. Adiponectin is a potential target for lifestyle and pharmacological interventions. Research on the possible role of HMW adiponectin in modifying cardiometabolic pathology in schizophrenia is needed.

AB - Background: Persons with schizophrenia and schizoaffective disorder (PwS) have high rates of cardiometabolic pathology that contributes to premature mortality. Adiponectin is a metabolic hormone affecting insulin sensitivity and inflammation, and is active in the brain. High-molecular weight (HMW) adiponectin is considered a more sensitive marker of metabolic dysfunction than total adiponectin, but has been poorly studied in schizophrenia. Methods: This was a cross-sectional study of 100 PwS, age range 26–68 years (46 women), and 93 age- and sex-comparable non-psychiatric comparison (NC) subjects. Assessments included measures of psychopathology, physical health, cognitive function, and circulating biomarkers of metabolic dysfunction (HMW adiponectin, lipids, insulin resistance) and inflammation (high-sensitivity C-reactive protein or hs-CRP, Tumor Necrosis Factor-α, Interleukin-6, and Interleukin-10). Results: HMW adiponectin levels were lower in PwS compared to NCs. Lower HMW adiponectin levels were associated with higher body mass index (BMI), higher Framingham risk for coronary heart disease, higher number of metabolic syndrome criteria, greater insulin resistance, lower HDL cholesterol, and higher hs-CRP in both groups. Only in PwS, lower HMW adiponectin correlated with younger age. In the best-fit regression models of HMW adiponectin, lower levels were associated with lower HDL cholesterol and minority race/ethnicity in both groups; but with younger age, non-smoking, higher insulin resistance, and a diagnosis of schizoaffective disorder only among PwS, and with male sex, better cognitive functioning, and higher hs-CRP levels in NCs only. Discussion: HMW adiponectin may be a promising biomarker of cardiometabolic health, especially among PwS. Adiponectin is a potential target for lifestyle and pharmacological interventions. Research on the possible role of HMW adiponectin in modifying cardiometabolic pathology in schizophrenia is needed.

KW - Adipokines

KW - Aging

KW - Body mass index

KW - Cytokines

KW - Hemoglobin A1C

KW - Insulin resistance

UR - http://www.scopus.com/inward/record.url?scp=85068175334&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85068175334&partnerID=8YFLogxK

U2 - 10.1016/j.jpsychires.2019.06.011

DO - 10.1016/j.jpsychires.2019.06.011

M3 - Article

C2 - 31276836

AN - SCOPUS:85068175334

VL - 117

SP - 31

EP - 37

JO - Journal of Psychiatric Research

JF - Journal of Psychiatric Research

SN - 0022-3956

ER -